Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Ieq Capital LLC

Ieq Capital LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 7.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 51,921 shares of the medical research company’s stock after acquiring an additional 3,757 shares during the quarter. Ieq Capital LLC’s holdings in Amgen were worth $16,222,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC grew its position in shares of Amgen by 48.9% in the second quarter. Intech Investment Management LLC now owns 53,109 shares of the medical research company’s stock valued at $16,594,000 after purchasing an additional 17,436 shares during the period. XTX Topco Ltd acquired a new stake in Amgen in the 2nd quarter worth about $661,000. Concorde Asset Management LLC boosted its holdings in Amgen by 4.8% in the 2nd quarter. Concorde Asset Management LLC now owns 888 shares of the medical research company’s stock worth $277,000 after buying an additional 41 shares during the last quarter. MRP Capital Investments LLC purchased a new stake in Amgen during the 2nd quarter worth approximately $219,000. Finally, Marathon Trading Investment Management LLC acquired a new position in shares of Amgen during the second quarter valued at approximately $469,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.9 %

Shares of NASDAQ:AMGN opened at $335.95 on Friday. The company has a market capitalization of $180.22 billion, a price-to-earnings ratio of 47.99, a PEG ratio of 2.93 and a beta of 0.61. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The business has a 50-day moving average price of $329.44 and a 200 day moving average price of $305.22. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same quarter in the prior year, the business earned $5.00 earnings per share. Amgen’s revenue was up 20.1% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Analyst Ratings Changes

A number of analysts have recently issued reports on AMGN shares. Morgan Stanley lowered their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 11th. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Argus boosted their price target on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $327.28.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.